Efficacy and Safety of Additional Injection of Autologous PRS during Transanal Advancement Flap Repair of Transsphincteric Cryptoglandular Perianal Fistulas

1Jeanine Arkenbosch*, 2Oddeke van Ruler, 3Jeroen Stevens, 3Eelco de Graaf, 2Ruud Schouten, 1Annemarie de Vries, 1Janneke van der Woude, 4Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, Netherlands; 2Department of Surgery, IJsselland Hospital, Capelle a/d IJssel, Netherlands; 3Department of Plastic and Reconstrucive Surgery, Bergman Clinic, The Hague, Netherlands

Background Treatment of transsphincteric cryptoglandular perianal fistulas is challenging and associated with high recurrence rates. Transanal Advancement Flap Repair (TAFR) fails in almost one of every three patients, probably due to persistent chronic inflammation. Autologous Platelet-rich Stroma (PRS), platelet-rich plasma (PRP) combined with progenitor cells from autologous stromal vascular fraction (SVF), obtained from liposuction, could suppress chronic inflammation and improve success rates in TAFR. This study aimed to assess the feasibility, safety and efficacy of additional injection of autologous PRS during TAFR of transsphincteric cryptoglandular fistulas.

Methods 22 patients with transsphincteric cryptoglandular fistulas who underwent TAFR between December 2017 and October 2018 were prospectively included after informed consent. All patients underwent standardized TAFR and standardized preparation of autologous PRS. Inclusion criteria were transsphincteric fistulas with only one internal opening (or a second one very close by) and absence of pelvic abscess. Clinical healing was defined as the absence of symptoms and closure of the external opening at physical examination.

Conclusions Eradication of H. pylori infection has minimal disruption of the microbiota, no effect on antibiotic resistance of E. coli and some positive effects on metabolic parameters. These collectively lend support to the long-term safety of H. pylori eradication therapy.
new model to existing models of model for end-stage liver disease (MELD), Child-Pugh scores and Glasgow Blatchford Score.

Results The 6-week overall mortality rate was 12.3%. Multivariate analysis showed that Mean Arterial Pressure (MAP), model for end-stage liver disease (MELD), high-risk stigmata of esophageal varices or peptic ulcer on endoscopic finding and the Glasgow Blatchford Score were independent predictors of mortality. A new logistic model using these variables was developed. This model’s AUROC was 0.934, which was significantly higher than that of MELD (0.721), MAP (0.842), and Glasgow Blatchford Score (0.904). Two external validation studies showed that the AUROC of our model was consistently higher than 0.954. (figure 1)

Conclusions Our new simplified model accurately and consistently predicted 6-week mortality in patients with acute varical bleeding using objective variables measured at admission. Our system can be used to identify high-risk acute varical bleeding patients.

IDDF2019-ABS-0079 IMPACT OF TIME-TO-SURGERY ON THE PROGNOSIS OF HEPATOCELLULAR CARCINOMA PATIENTS AT BCLC STAGE 0-A AFTER LIVER RESECTION

Mengchao Wei*, Shuling Chen, Zhenwei Peng, Zebin Chen, Han Xiao, Ming Kuang. The First Affiliated Hospital of Sun Yat-sen University, China

Background Long waiting time before surgery caused by preoperative interventions may lead to tumor progression and worse prognosis in patients with hepatocellular carcinoma (HCC). The impact of time-to-surgery (TTS) on the prognosis of HCC patients has not been well illustrated in Chinese HCC patients. We tried to clarify the TTS issue in this study in order to provide new perspectives for making rational treatment timing for surgery.

Methods We enrolled 1051 HCC patients at BCLC stage 0-A with primary liver resection from three centers in China. Patients were divided into two groups according to different cut-off values of TTS (14 days, 21 days, 28 days, 35 days, 42 days). The primary endpoints were recurrence-free survival (RFS) and overall survival (OS).

Results The median TTS of HCC patients at BCLC stage 0-A was 14 days. Patients in the longer TTS group had significantly longer RFS and OS than those in the shorter TTS group when cut off values of TTS were 28 (RFS: \( P = 0.044 \); OS: \( P = 0.004 \)) and 35 (RFS: \( P = 0.016 \); OS: \( P = 0.044 \)). TTS did not produce a significant impact on patients’ RFS and OS when cut off values were 14, 21 and 42 days.

Conclusions TTS between 28 and 42 days may be appropriate for Chinese HCC patients at BCLC stage 0-A to receive surgery.

IDDF2019-ABS-0108 HEPATIC DECOMPENSATION RISK IS REDUCED, BUT NOT ELIMINATED AFTER DIRECT-ACTING ANTIVIRALS: THE ROLE OF Spleen Stiffness MEASUREMENT

1Giovanni Marasco*, 1Elton Dajti, 1Federico Ravaioli, 2Antonio Colecchia, 1Maria Letizia Bacchi Reggiani, 2Agostino Colli, 1Luigina Vanessa Alemanni, 1Maria Rosa Tame, 1Pietro Andreone, 1Stefano Brilliati, 1Francesco Azzaroli, 1Giuseppe Mazzella, 1Davide Festi, 1University of Bologna, Italy; 2Bergo Trento Hospital Verona, Italy; 3A. Marzuni Hospital Lecco, Italy

10.1136/gutjnl-2019-IDDFabstracts.13

Background Little evidence is available on the risk of hepatic decompensation (HD), mainly those related to portal hypertension (PH), after direct-acting antivirals (DAAs) in patients with HCV-related advanced chronic liver disease (ACLD). Our aims were: a) to evaluate the incidence of HD after DAAs, as well as the effect of such treatments on HD development and b) to assess the role of liver (LSM) and spleen (SSM) stiffness measurement in HD prediction after sustained virologic response (SVR).

Methods We performed in our tertiary centre a cohort study in 146 ACLD patients treated with DAAs and with available LSM and SSM both before and 6 months after end-of-treatment (EOT). A historical cohort of 92 consecutively enrolled untreated cirrhotic patients with active HCV-infection was used as a control group. A propensity score stabilized inverse probability weighting approach was used to account for differences between groups. Time-dependent models for HD prediction after SVR were applied to account for changes in LSM and SSM after DAA therapy.

Results Median follow-up in the DAA cohort was 33.5 (22 – 38) months. The incidence of HD was 7.07 per 100 person-years (PYs). DAA therapy was an independent protective factor for HD development (hazard ratio [HR], 0.177; 95% confidence interval-of-confidence [CI], 0.081–0.390) (figure 1A), whereas previous HD (HR, 5.982; 95% CI 2.434–14.702) and higher SSM values (HR, 1.025; 95% CI 1.006–1.045) were associated with a higher risk of the event. SSM≥254 kPa was independently associated with HD despite SVR achievement (HR, 4.678;